Exelixis CL184-313
Laufzeit: 01.01.2020 - 31.12.2023
Laufzeit: 01.01.2020 - 31.12.2023
A Randomized, Double-Blind, Controlled Phase 3 Study of
Cabozantinib in Combination with Nivolumab and Ipilimumab
versus Nivolumab and Ipilimumab in Subjects with Previously
Untreated Advanced or Metastatic Renal Cell Carcinoma of
Intermediate or Poor Risk